Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1186/s13045-021-01222-y

http://scihub22266oqcxt.onion/10.1186/s13045-021-01222-y
suck pdf from google scholar
35012610!8744064!35012610
unlimited free pdf from europmc35012610    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid35012610      J+Hematol+Oncol 2022 ; 15 (1): 5
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology #MMPMID35012610
  • Song NJ; Allen C; Vilgelm AE; Riesenberg BP; Weller KP; Reynolds K; Chakravarthy KB; Kumar A; Khatiwada A; Sun Z; Ma A; Chang Y; Yusuf M; Li A; Zeng C; Evans JP; Bucci D; Gunasena M; Xu M; Liyanage NPM; Bolyard C; Velegraki M; Liu SL; Ma Q; Devenport M; Liu Y; Zheng P; Malvestutto CD; Chung D; Li Z
  • J Hematol Oncol 2022[Jan]; 15 (1): 5 PMID35012610show ga
  • BACKGROUND: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) through direct lysis of infected lung epithelial cells, which releases damage-associated molecular patterns and induces a pro-inflammatory cytokine milieu causing systemic inflammation. Anti-viral and anti-inflammatory agents have shown limited therapeutic efficacy. Soluble CD24 (CD24Fc) blunts the broad inflammatory response induced by damage-associated molecular patterns via binding to extracellular high mobility group box 1 and heat shock proteins, as well as regulating the downstream Siglec10-Src homology 2 domain-containing phosphatase 1 pathway. A recent randomized phase III trial evaluating CD24Fc for patients with severe COVID-19 (SAC-COVID; NCT04317040) demonstrated encouraging clinical efficacy. METHODS: Using a systems analytical approach, we studied peripheral blood samples obtained from patients enrolled at a single institution in the SAC-COVID trial to discern the impact of CD24Fc treatment on immune homeostasis. We performed high dimensional spectral flow cytometry and measured the levels of a broad array of cytokines and chemokines to discern the impact of CD24Fc treatment on immune homeostasis in patients with COVID-19. RESULTS: Twenty-two patients were enrolled, and the clinical characteristics from the CD24Fc vs. placebo groups were matched. Using high-content spectral flow cytometry and network-level analysis, we found that patients with severe COVID-19 had systemic hyper-activation of multiple cellular compartments, including CD8(+) T cells, CD4(+) T cells, and CD56(+) natural killer cells. Treatment with CD24Fc blunted this systemic inflammation, inducing a return to homeostasis in NK and T cells without compromising the anti-Spike protein antibody response. CD24Fc significantly attenuated the systemic cytokine response and diminished the cytokine coexpression and network connectivity linked with COVID-19 severity and pathogenesis. CONCLUSIONS: Our data demonstrate that CD24Fc rapidly down-modulates systemic inflammation and restores immune homeostasis in SARS-CoV-2-infected individuals, supporting further development of CD24Fc as a novel therapeutic against severe COVID-19.
  • |Aged[MESH]
  • |Alarmins/immunology/metabolism[MESH]
  • |CD24 Antigen/chemistry/*therapeutic use[MESH]
  • |COVID-19/immunology/*prevention & control/virology[MESH]
  • |Cytokine Release Syndrome/immunology/metabolism/*prevention & control[MESH]
  • |Double-Blind Method[MESH]
  • |Female[MESH]
  • |HMGB1 Protein/immunology/metabolism[MESH]
  • |Heat-Shock Proteins/immunology/metabolism[MESH]
  • |Homeostasis/drug effects/immunology[MESH]
  • |Humans[MESH]
  • |Inflammation/immunology/metabolism/*prevention & control[MESH]
  • |Killer Cells, Natural/immunology/metabolism/virology[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |SARS-CoV-2/*drug effects/immunology/physiology[MESH]
  • |Solubility[MESH]
  • |T-Lymphocytes/immunology/metabolism/virology[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box